Gut microbiota and metabolites of α-synuclein transgenic monkey models with early stage of Parkinson's disease.
Journal
NPJ biofilms and microbiomes
ISSN: 2055-5008
Titre abrégé: NPJ Biofilms Microbiomes
Pays: United States
ID NLM: 101666944
Informations de publication
Date de publication:
02 09 2021
02 09 2021
Historique:
received:
30
03
2021
accepted:
02
08
2021
entrez:
3
9
2021
pubmed:
4
9
2021
medline:
7
1
2022
Statut:
epublish
Résumé
Parkinson's disease (PD) is the second most prevalent neurodegenerative disease. However, it is unclear whether microbiota and metabolites have demonstrated changes at early PD due to the difficulties in diagnosis and identification of early PD in clinical practice. In a previous study, we generated A53T transgenic monkeys with early Parkinson's symptoms, including anxiety and cognitive impairment. Here we analyzed the gut microbiota by metagenomic sequencing and metabolites by targeted gas chromatography. The gut microbiota analysis showed that the A53T monkeys have higher degree of diversity in gut microbiota with significantly elevated Sybergistetes, Akkermansia, and Eggerthella lenta compared with control monkeys. Prevotella significantly decreased in A53T transgenic monkeys. Glyceric acid, L-Aspartic acid, and p-Hydroxyphenylacetic acid were significantly elevated, whereas Myristic acid and 3-Methylindole were significantly decreased in A53T monkeys. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (KO0131) and the oxidative phosphorylation reaction (KO2147) were significantly increased in metabolic pathways of A53T monkeys. Our study suggested that the transgenic A53T and α-syn aggregation may affect the intestine microbiota and metabolites of rhesus monkeys, and the identified five compositional different metabolites that are mainly associated with mitochondrial dysfunction may be related to the pathogenesis of PD.
Identifiants
pubmed: 34475403
doi: 10.1038/s41522-021-00242-3
pii: 10.1038/s41522-021-00242-3
pmc: PMC8413421
doi:
Substances chimiques
alpha-Synuclein
0
Glyceraldehyde-3-Phosphate Dehydrogenases
EC 1.2.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
69Informations de copyright
© 2021. The Author(s).
Références
Curr Opin Pharmacol. 2013 Dec;13(6):869-74
pubmed: 23978504
Parkinsonism Relat Disord. 2016 Nov;32:66-72
pubmed: 27591074
J Biol Chem. 2007 Sep 7;282(36):26562-74
pubmed: 17613523
Exp Neurol. 2009 Aug;218(2):235-46
pubmed: 19303005
Nature. 2017 Nov 30;551(7682):648-652
pubmed: 29168502
Front Aging Neurosci. 2018 Jan 08;9:441
pubmed: 29358918
J Histochem Cytochem. 2015 Jan;63(1):57-68
pubmed: 25362140
Surg Neurol Int. 2017 Apr 26;8:65
pubmed: 28540131
Brain Res. 2016 Oct 1;1648(Pt A):193-201
pubmed: 27423518
Nat Commun. 2019 May 16;10(1):2200
pubmed: 31097702
Science. 1999 May 21;284(5418):1322-8
pubmed: 10334981
J Parkinsons Dis. 2020;10(1):185-192
pubmed: 31561385
Cell Rep. 2019 Nov 12;29(7):1767-1777.e8
pubmed: 31722195
Cell. 2019 May 30;177(6):1600-1618.e17
pubmed: 31150625
Neurobiol Dis. 2018 Jan;109(Pt B):249-257
pubmed: 28400134
Neuron. 2019 Aug 21;103(4):627-641.e7
pubmed: 31255487
ACS Chem Neurosci. 2018 Feb 21;9(2):141-150
pubmed: 29220570
Lancet. 2021 Jun 12;397(10291):2284-2303
pubmed: 33848468
Science. 2019 Jun 14;364(6445):
pubmed: 31196984
Mol Neurodegener. 2017 Nov 13;12(1):84
pubmed: 29132391
Mov Disord. 2019 Mar;34(3):396-405
pubmed: 30576008
Brain Res. 2009 Jul 7;1279:1-8
pubmed: 19445904
J Neurosci. 2016 Oct 12;36(41):10510-10521
pubmed: 27733604
NPJ Parkinsons Dis. 2021 Mar 10;7(1):27
pubmed: 33692356
Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S1-5
pubmed: 20082965
ACS Chem Neurosci. 2020 Oct 21;11(20):3267-3276
pubmed: 32941730
Mov Disord. 2017 May;32(5):739-749
pubmed: 28195358
Mov Disord. 2015 Sep;30(10):1351-60
pubmed: 26179554
Mov Disord. 2018 Jan;33(1):48-57
pubmed: 28843014
Sci Transl Med. 2016 Dec 7;8(368):368ra174
pubmed: 27928028
Sci China Life Sci. 2017 Nov;60(11):1223-1233
pubmed: 28536926
JAMA. 2020 Feb 11;323(6):548-560
pubmed: 32044947
World J Gastroenterol. 2017 May 28;23(20):3643-3654
pubmed: 28611517
Lipids. 2016 Aug;51(8):897-903
pubmed: 27206979
J Neurosci. 2014 Jan 1;34(1):249-59
pubmed: 24381286
Neuron. 2010 Jun 10;66(5):646-61
pubmed: 20547124
Adv Exp Med Biol. 2012;942:3-37
pubmed: 22399416
Hum Mol Genet. 2015 Apr 15;24(8):2308-17
pubmed: 25552648
Can J Neurol Sci. 2012 Mar;39(2):185-8
pubmed: 22343151
Brain Behav Immun. 2018 May;70:194-202
pubmed: 29501802
J Neuroinflammation. 2019 Jun 27;16(1):129
pubmed: 31248424
Eur J Pharmacol. 2017 Dec 15;817:86-95
pubmed: 28549787
EBioMedicine. 2019 Jun;44:691-707
pubmed: 31221587
Mov Disord. 2011 Mar;26(4):653-8
pubmed: 21370256
Mov Disord. 2015 Mar;30(3):350-8
pubmed: 25476529
Anal Chem. 2017 May 16;89(10):5565-5577
pubmed: 28437060
J Neurogastroenterol Motil. 2018 Jan 30;24(1):30-42
pubmed: 29291606
Int J Syst Evol Microbiol. 2004 Sep;54(Pt 5):1469-1476
pubmed: 15388697
Mov Disord. 2018 Jan;33(1):88-98
pubmed: 28843021
Immunity. 2014 Jan 16;40(1):128-39
pubmed: 24412617
Lancet Neurol. 2019 May;18(5):459-480
pubmed: 30879893
Trends Endocrinol Metab. 2018 May;29(5):286-288
pubmed: 29478695
Clin Dev Immunol. 2013;2013:526860
pubmed: 24324507
Am J Physiol Cell Physiol. 2016 Aug 1;311(2):C237-8
pubmed: 27413172
Sci Transl Med. 2016 Jun 8;8(342):342ra78
pubmed: 27280685
Brain Res. 2017 Jul 15;1667:41-45
pubmed: 28506555